First Header Logo Second Header Logo

Connection

Steven Feldman to Biological Products

Back to Details
This is a "connection" page, showing publications Steven Feldman has written about Biological Products.
Steven Feldman
Connection Strength
16.635
Biological Products
  1. Ghamrawi R, Bell KA, Balogh EA, Strowd LC, Feldman SR. Current and emerging biologics for the treatment of pediatric atopic dermatitis. Expert Opin Biol Ther. 2020 12; 20(12):1435-1445.
    View in: PubMed
    Score: 0.669
  2. Bray JK, Feldman SR. The ethical implications of utilizing advertising techniques to increase biologic treatment willingness in patients with psoriasis. Dermatol Online J. 2020 Jul 15; 26(7).
    View in: PubMed
    Score: 0.654
  3. Bashyam AM, Feldman SR. Should patients stop their biologic treatment during the COVID-19 pandemic. J Dermatolog Treat. 2020 06; 31(4):317-318.
    View in: PubMed
    Score: 0.639
  4. Haidari W, Pona A, Feldman SR. Management of Residual Psoriasis in Patients on Biologic Treatment J Drugs Dermatol. 2020 Feb 02; 19(2):188-194.
    View in: PubMed
    Score: 0.634
  5. Nadkarni A, Hyde K, Cardwell LA, Feldman SR. Biologics monitoring: incongruity between recommendations and clinician monitoring trends. J Dermatolog Treat. 2020 Aug; 31(5):450-451.
    View in: PubMed
    Score: 0.631
  6. Bray JK, Cline A, Feldman SR. Assessing perceived adverse effects of biologic medications for patients with psoriasis. J Am Acad Dermatol. 2020 03; 82(3):766-768.
    View in: PubMed
    Score: 0.623
  7. Cohen SR, Pona A, Cline AE, Feldman SR. The complexity of adverse event assessment and counseling for patients on biologic treatment. Expert Rev Clin Immunol. 2019 08; 15(8):809-811.
    View in: PubMed
    Score: 0.610
  8. Stiff KM, Cline A, Feldman SR. Tracking the price of existing biologics when drugs enter the market. Expert Rev Pharmacoecon Outcomes Res. 2019 Aug; 19(4):375-377.
    View in: PubMed
    Score: 0.606
  9. Kolli SS, Kepley AL, Cline A, Feldman SR. A safety review of recent advancements in the treatment of psoriasis: analysis of clinical trial safety data. Expert Opin Drug Saf. 2019 06; 18(6):523-536.
    View in: PubMed
    Score: 0.603
  10. Feldman SR, Pelletier CL, Wilson KL, Mehta RK, Brouillette MA, Smith D, Bonafede MM. Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis. J Comp Eff Res. 2019 07; 8(9):699-709.
    View in: PubMed
    Score: 0.603
  11. Wechter T, Seger EW, Cline A, Feldman SR. Can We Tell Patients That IL-23 and TNF-a Inhibition Are "Natural" Ways to Treat Psoriasis? J Cutan Med Surg. 2019 May/Jun; 23(3):337-338.
    View in: PubMed
    Score: 0.601
  12. Feldman SR, Regnier SA, Chirilov A, Hey F, Gilloteau I, Cella D. Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States. J Am Acad Dermatol. 2019 Jun; 80(6):1650-1657.
    View in: PubMed
    Score: 0.591
  13. Wu JJ, Lu M, Veverka KA, Smulders M, Papademetriou E, Yu J, Feldman SR. The journey for US psoriasis patients prescribed a topical: a retrospective database evaluation of patient progression to oral and/or biologic treatment. J Dermatolog Treat. 2019 Aug; 30(5):446-453.
    View in: PubMed
    Score: 0.586
  14. Bartos G, Cline A, Beroukhim K, Burrall BA, Feldman SR. Current biological therapies for use in HIV-positive patients with psoriasis: case report of gesulkumab used and review. Dermatol Online J. 2018 Nov 15; 24(11).
    View in: PubMed
    Score: 0.583
  15. Feldman SR, Pelletier CL, Wilson KL, Mehta RK, Brouillette MA, Smith D, Bonafede MM. Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics. J Comp Eff Res. 2019 01; 8(1):45-54.
    View in: PubMed
    Score: 0.581
  16. Seger EW, Wechter T, Strowd L, Feldman SR. Relative efficacy of systemic treatments for atopic dermatitis. J Am Acad Dermatol. 2019 Feb; 80(2):411-416.e4.
    View in: PubMed
    Score: 0.578
  17. Aleshaki JS, Cardwell LA, Muse ME, Feldman SR. Adherence and resource use among psoriasis patients treated with biologics. Expert Rev Pharmacoecon Outcomes Res. 2018 12; 18(6):609-617.
    View in: PubMed
    Score: 0.575
  18. Feldman SR, Wu JJ, Rastogi S, Menges B, Lingohr-Smith M, Lin J. The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans. J Med Econ. 2018 May; 21(5):537-541.
    View in: PubMed
    Score: 0.552
  19. Seale L, Cardwell LA, Feldman SR. Adherence to biologics in patients with psoriasis. Expert Rev Clin Immunol. 2018 02; 14(2):155-161.
    View in: PubMed
    Score: 0.550
  20. Patel N, Nadkarni A, Cardwell LA, Vera N, Frey C, Patel N, Feldman SR. Psoriasis, Depression, and Inflammatory Overlap: A Review. Am J Clin Dermatol. 2017 Oct; 18(5):613-620.
    View in: PubMed
    Score: 0.539
  21. Amato DA, Malatestinic WN, Palmgren MC, Feldman SR. Dermatologists: Collaborating With Payers to Optimize Coverage Policies. J Drugs Dermatol. 2017 Mar 01; 16(3):228-232.
    View in: PubMed
    Score: 0.517
  22. Bartos S, Hill D, Feldman SR. Review of maintenance of response to psoriasis treatments. J Dermatolog Treat. 2016 Aug; 27(4):293-7.
    View in: PubMed
    Score: 0.497
  23. James SM, Hill DE, Feldman SR. Costs of Common Psoriasis Medications, 2010-2014. J Drugs Dermatol. 2016 Mar; 15(3):305-8.
    View in: PubMed
    Score: 0.483
  24. Feldman SR, Zhao Y, Shi L, Tran MH. Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis. J Manag Care Spec Pharm. 2015 Oct; 21(10):874-88.
    View in: PubMed
    Score: 0.469
  25. West C, Narahari S, O'Neill J, Davis S, Huynh M, Clark A, Boles A, Feldman SR. Adherence to adalimumab in patients with moderate to severe psoriasis. Dermatol Online J. 2013 May 15; 19(5):18182.
    View in: PubMed
    Score: 0.398
  26. Feldman SR, Koo JY, Johnson LA, Preston NJ. Clobetasol propionate spray 0.05% add-on therapy to a stable regimen of biologic treatment in patients with moderate to very severe plaque psoriasis. Cutis. 2009 Oct; 84(4 Suppl):25-32.
    View in: PubMed
    Score: 0.310
  27. Stein KR, Pearce DJ, Feldman SR. The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Semin Cutan Med Surg. 2005 Mar; 24(1):52-7.
    View in: PubMed
    Score: 0.225
  28. Li W, Ghamrawi R, Haidari W, Feldman SR. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis. Ann Pharmacother. 2020 04; 54(4):380-387.
    View in: PubMed
    Score: 0.156
  29. Baumrin E, Van Voorhees A, Garg A, Feldman SR, Merola JF. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2019 Jul; 81(1):102-110.
    View in: PubMed
    Score: 0.149
  30. Glines KR, Stiff KM, Freeze M, Cline A, Strowd LC, Feldman SR. An update on the topical and oral therapy options for treating pediatric atopic dermatitis. Expert Opin Pharmacother. 2019 04; 20(5):621-629.
    View in: PubMed
    Score: 0.147
  31. Stiff KM, Glines KR, Porter CL, Cline A, Feldman SR. Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis. Expert Rev Clin Pharmacol. 2018 Dec; 11(12):1209-1218.
    View in: PubMed
    Score: 0.146
  32. Guda A, Feldman SR, Strowd L. Investigational drugs in phase II clinical trials for moderate to severe plaque psoriasis - potential new treatments on the horizon. Expert Opin Investig Drugs. 2018 11; 27(11):931-939.
    View in: PubMed
    Score: 0.145
  33. Al Sawah S, Foster SA, Goldblum OM, Malatestinic WN, Zhu B, Shi N, Song X, Feldman SR. Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis. J Med Econ. 2017 Sep; 20(9):982-990.
    View in: PubMed
    Score: 0.133
  34. Hoffman MB, Hill D, Feldman SR. Current challenges and emerging drug delivery strategies for the treatment of psoriasis. Expert Opin Drug Deliv. 2016 Oct; 13(10):1461-73.
    View in: PubMed
    Score: 0.123
  35. Vaidya TS, Anderson KL, Feldman SR. Even well-controlled psoriasis patients have unmet treatment needs regardless of disease severity. Dermatol Online J. 2015 Sep 17; 21(9).
    View in: PubMed
    Score: 0.117
  36. Strowd LC, Yentzer BA, Fleischer AB, Feldman SR. Increasing use of more potent treatments for psoriasis. J Am Acad Dermatol. 2009 Mar; 60(3):478-81.
    View in: PubMed
    Score: 0.073
  37. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008 May; 58(5):826-50.
    View in: PubMed
    Score: 0.070
  38. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, Van Voorhees AS, Elmets CA, Leonardi CL, Beutner KR, Bhushan R, Menter A. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008 May; 58(5):851-64.
    View in: PubMed
    Score: 0.070
  39. Price J, Bhosle M, Feldman SR, Balkrishnan R. Outcomes associated with the use of biologic agents in moderate to severe psoriasis. J Drugs Dermatol. 2007 Mar; 6(3):259-67.
    View in: PubMed
    Score: 0.065
  40. Pearce DJ, Higgins KB, Stealey KH, Balkrishnan R, Crane MM, Camacho F, Fleischer AB, Feldman SR. Adverse events from systemic therapies for psoriasis are common in clinical practice. J Dermatolog Treat. 2006; 17(5):288-93.
    View in: PubMed
    Score: 0.060
  41. Bhosle MJ, Feldman SR, Camacho FT, Timothy Whitmire J, Nahata MC, Balkrishnan R. Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis. J Dermatolog Treat. 2006; 17(5):294-301.
    View in: PubMed
    Score: 0.060
  42. Simpson GL, Yelverton CB, Rittenberg S, Feldman SR. Do utilization management controls for phototherapy increase the prescription of biologics? J Dermatolog Treat. 2006; 17(6):359-61.
    View in: PubMed
    Score: 0.060
  43. Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo Re V, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Gondo G, Heydon S, Koons S, Ritchlin CT. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. J Am Acad Dermatol. 2021 05; 84(5):1254-1268.
    View in: PubMed
    Score: 0.042
  44. Wu JJ, Feldman SR, Rastogi S, Menges B, Lingohr-Smith M, Lin J. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States. J Dermatolog Treat. 2018 Dec; 29(8):769-774.
    View in: PubMed
    Score: 0.035
  45. Asche CV, Kim M, Feldman SR, Zografos P, Lu M. Budget impact model in moderate-to-severe psoriasis vulgaris assessing effects of calcipotriene and betamethasone dipropionate foam on per-patient standard of care costs. J Med Econ. 2017 Sep; 20(9):1000-1006.
    View in: PubMed
    Score: 0.033
  46. Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015 Feb; 26(1):23-31.
    View in: PubMed
    Score: 0.026
  47. Lin HC, Lucas PT, Feldman SR, Balkrishnan R. Medication use and associated health care outcomes and costs for patients with psoriasis in the United States. J Dermatolog Treat. 2012 Jun; 23(3):196-202.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.